-
1.发明申请公开(公告)号：US20200281871A1
公开(公告)日：2020-09-10
申请号：US16811759
申请日：2020-03-06
IPC分类号： A61K31/12 , A61K9/127 , A61K47/24 , A61K31/355 , A61K31/375 , A61K31/385 , A61K31/145 , A61K31/16 , A61K31/7048 , A61K47/10 , A61K47/34
摘要： The present invention relates to novel tetrahydrocurcumin (THCu) compositions, novel methods of manufacturing, and methods of using these compositions for therapeutic applications. The novel synthetic pathway(s) result in THCu compositions that generally lack hexahydrocurcumin (HHC), and include an improved impurity profile with reduced additional species that are generally present in hydrogenated curcumin compositions.
-
公开(公告)号：US20210322340A1
公开(公告)日：2021-10-21
申请号：US17210205
申请日：2021-03-23
摘要： The present invention involves a novel method for treatment of chronic kidney disease comprising administering a compound that induces a stress protein response in a patient, and administering a potent antioxidant if the patent's response is below a predefined level. It also involves a quantitative measure for determining a patient's antioxidant reserve capacity.
-
公开(公告)号：US20210338708A1
公开(公告)日：2021-11-04
申请号：US17205521
申请日：2021-03-18
IPC分类号： A61K31/714 , A61K33/30 , A61K33/24 , A61K47/54 , A61K9/00 , A61P31/14 , A01N25/34 , A01N55/04 , A01N55/02 , A61L9/012
摘要： The present invention involves a novel method for treatment of coronavirus infection, including SARS-COV-2. The method comprises administering stannous protoporphyrin and/or cyanocobalamin to a human patient at risk for developing complications from coronavirus infection. The method is particularly useful where a patient has been diagnosed with coronavirus infection or has been exposed to coronavirus but has not developed symptoms of coronavirus infection.
-
公开(公告)号：US20210308074A9
公开(公告)日：2021-10-07
申请号：US16811759
申请日：2020-03-06
IPC分类号： A61K31/12 , A61K9/127 , A61K47/24 , A61K31/355 , A61K31/375 , A61K31/385 , A61K31/145 , A61K31/16 , A61K31/7048 , A61K47/10 , A61K47/34
摘要： The present invention relates to novel tetrahydrocurcumin (THCu) compositions, novel methods of manufacturing, and methods of using these compositions for therapeutic applications. The novel synthetic pathway(s) result in THCu compositions that generally lack hexahydrocurcumin (HHC), and include an improved impurity profile with reduced additional species that are generally present in hydrogenated curcumin compositions.
-
-
-
搜索结果
4 条记录 (耗时 0.011 秒)
